BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 01/23/23

COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data ind...

New research has found that some T cells secrete cytokines that may help fight against fungal infections and autoimmune illnesses. T cells are a type of white blood cell that help protect the body against infection . Different T cells have different functions in helping fight infection. T helper...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced statistically significant (p<0.001) efficacy results in a precl...

The United States is currently facing a critical shortage of infectious disease experts . Infectious disease doctors, or IDs as they are commonly referred to in hospitals, are usually tasked with diagnosing diseases and guiding hospital teams in treatment. This tends to involve collecting exte...

BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept...

Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placebo Result builds on recently announced data indicating NanoAb treatmen...

BiondVax Pharmaceuticals (NASDAQ: BVXV) CEO Amir Reichman will be presenting at the Biotech Showcase Conference, scheduled for Jan. 9–11, 2023. The conference is being held in San Francisco during the J.P. Morgan 41st annual Healthcare Conference. BiondVax board chair Mark Germain will al...

JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmun...

BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Exp...